Patents by Inventor Catherine Brautigam Beidler

Catherine Brautigam Beidler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS TARGETING EPIREGULIN
    Publication number: 20220372124
    Abstract: The present invention relates to epiregulin antibodies, compositions comprising the same, and methods of making and/or using the antibodies and/or compositions thereof for chronic pain disorders such as chronic osteoarthritis pain, or chronic diabetic peripheral neuropathy pain, or chronic low back pain.
    Type: Application
    Filed: May 19, 2022
    Publication date: November 24, 2022
    Inventors: Catherine Brautigam Beidler, Jeffrey Streetman Boyles, Daniel Scott Girard, Shannon Marie Harlan, Michael Parvin Johnson
  • ANTI-PACAP ANTIBODY
    Publication number: 20210171616
    Abstract: Nucleic acids comprising sequences that encode antibodies to human pituitary adenylate cyclase-activating peptide for the manufacture of antibodies to human pituitary adenylate cyclase-activating peptide.
    Type: Application
    Filed: February 15, 2021
    Publication date: June 10, 2021
    Inventors: Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
  • Anti-PACAP antibody
    Patent number: 10954292
    Abstract: Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: March 23, 2021
    Assignee: Eli Lilly and Company
    Inventors: Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
  • Pan-ELR+ CXC chemokine antibodies
    Patent number: 10858425
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: December 8, 2020
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • ANTI-PACAP ANTIBODY
    Publication number: 20200131256
    Abstract: Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
    Type: Application
    Filed: November 22, 2019
    Publication date: April 30, 2020
    Inventors: Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
  • Anti-TrkA antibody
    Patent number: 10618974
    Abstract: Antibodies to tropomysin receptor kinase (TrkA), compositions including such antibodies, and methods of using such antibodies for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: April 14, 2020
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Daniel Scott Girard, Chetankumar Natvarlal Patel
  • Anti-PACAP antibody
    Patent number: 10519225
    Abstract: Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: December 31, 2019
    Assignee: Eli Lilly and Company
    Inventors: Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
  • ANTI-TRKA ANTIBODY
    Publication number: 20190263932
    Abstract: Antibodies to tropomysin receptor kinase (TrkA), compositions including such antibodies, and methods of using such antibodies for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.
    Type: Application
    Filed: February 21, 2019
    Publication date: August 29, 2019
    Inventors: Catherine Brautigam Beidler, Daniel Scott Girard, Chetankumar Natvarlal Patel
  • ANTI-PACAP ANTIBODY
    Publication number: 20190100579
    Abstract: Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
    Type: Application
    Filed: September 20, 2018
    Publication date: April 4, 2019
    Inventors: Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
  • Pan-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20180362631
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 20, 2018
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • ANTI-CGRP/ANTI-IL-23 BISPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20180291093
    Abstract: Bispecific antibodies are provided that bind Calcitonin Gene Related Peptide (CGRP) and Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CGRP and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Psoriatic Arthritis (PsA) and ankylosing spondylitis (AS).
    Type: Application
    Filed: October 30, 2015
    Publication date: October 11, 2018
    Applicant: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Rohn L Millican, JR., Barrett Allan, Catherine Brautigam Beidler
  • Pan-ELR+ CXC chemokine antibodies
    Patent number: 10093727
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 9, 2018
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher, Sudhakar Reddy Chintharlapalli
  • Pan-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20170362315
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 21, 2017
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • Pan-ELR CXC chemokine antibodies
    Patent number: 9783605
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: October 10, 2017
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Derrick Ryan Witcher, Beth Ann Strifler
  • ANTIBODIES THAT BIND IL-23
    Publication number: 20170275356
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 28, 2017
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • Nucleic acids encoding antibodies that bind IL-23
    Patent number: 9688753
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: June 27, 2017
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • PAN-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20160152699
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: February 3, 2016
    Publication date: June 2, 2016
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Derrick Ryan Witcher, Beth Ann Strifler
  • Pan-ELR+ CXC Chemokine Antibodies
    Patent number: 9290570
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: March 22, 2016
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • ANTIBODIES THAT BIND IL-23
    Publication number: 20150232552
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Application
    Filed: May 1, 2015
    Publication date: August 20, 2015
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • Antibodies that bind to IL-23
    Patent number: 9023358
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: May 5, 2015
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly